JP4668612B2 - トロンビンペプチド誘導体ダイマー - Google Patents

トロンビンペプチド誘導体ダイマー Download PDF

Info

Publication number
JP4668612B2
JP4668612B2 JP2004519705A JP2004519705A JP4668612B2 JP 4668612 B2 JP4668612 B2 JP 4668612B2 JP 2004519705 A JP2004519705 A JP 2004519705A JP 2004519705 A JP2004519705 A JP 2004519705A JP 4668612 B2 JP4668612 B2 JP 4668612B2
Authority
JP
Japan
Prior art keywords
gly
subject
thrombin
treatment
dimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004519705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006507229A5 (enExample
JP2006507229A (ja
Inventor
カーニー，ダレル，エイチ．
Original Assignee
ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム filed Critical ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム
Publication of JP2006507229A publication Critical patent/JP2006507229A/ja
Publication of JP2006507229A5 publication Critical patent/JP2006507229A5/ja
Application granted granted Critical
Publication of JP4668612B2 publication Critical patent/JP4668612B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2004519705A 2002-07-02 2003-07-01 トロンビンペプチド誘導体ダイマー Expired - Fee Related JP4668612B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39357902P 2002-07-02 2002-07-02
PCT/US2003/020626 WO2004005317A2 (en) 2002-07-02 2003-07-01 Thrombin peptide derivative dimers

Publications (3)

Publication Number Publication Date
JP2006507229A JP2006507229A (ja) 2006-03-02
JP2006507229A5 JP2006507229A5 (enExample) 2006-08-17
JP4668612B2 true JP4668612B2 (ja) 2011-04-13

Family

ID=30115603

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004519705A Expired - Fee Related JP4668612B2 (ja) 2002-07-02 2003-07-01 トロンビンペプチド誘導体ダイマー

Country Status (8)

Country Link
US (2) US7456250B2 (enExample)
EP (1) EP1539800B1 (enExample)
JP (1) JP4668612B2 (enExample)
AT (1) ATE362939T1 (enExample)
AU (1) AU2003247848B2 (enExample)
CA (1) CA2491135A1 (enExample)
DE (1) DE60313982T2 (enExample)
WO (1) WO2004005317A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004005564T2 (de) * 2003-12-31 2007-12-13 Orthologic Corp., Tempe Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
CA2663547C (en) * 2006-09-22 2020-08-25 Orthologic Corp. Method of treating endothelial dysfunction
WO2008100567A2 (en) * 2007-02-15 2008-08-21 Orthologic Corp. Thrombin peptide derivatives for treating fractures in osteopenic patients
WO2008124172A1 (en) * 2007-04-10 2008-10-16 The Board Of Regents, The University Of Texas System Combination therapy for chronic dermal ulcers
EP2155236A1 (en) * 2007-04-10 2010-02-24 The Board of Regents,The University of Texas System Combination therapy for cardiac revascularization and cardiac repair
AU2009229395A1 (en) * 2008-03-26 2009-10-01 The Board Of Regents, The University Of Texas System Method of treating degenerative diseases
US20110117075A1 (en) * 2008-03-26 2011-05-19 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
EP2268304A2 (en) * 2008-03-26 2011-01-05 Orthologic Corp. Methods for treating acute myocardial infarction
WO2009120307A2 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
CU23716A1 (es) * 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech Péptido antagonista de la actividad de la interleucina-15
CA2802176A1 (en) 2010-06-11 2011-12-15 The Board Of Regents, The University Of Texas System Methods of mitigating effects of radiation and reducing the risk of systemic infection
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
WO2020210087A1 (en) * 2019-04-12 2020-10-15 Affirmed Pharma, Llc Rusalatide acetate compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US6500934B1 (en) * 1996-07-24 2002-12-31 Michael Rush Lerner Bivalent agonists for G-protein coupled receptors
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
ATE254925T1 (de) 2000-07-19 2003-12-15 Univ Texas Stimulierung des knochenwachstums mit peptidderivaten von thrombin
CN1458974A (zh) 2000-07-20 2003-11-26 德克萨斯系统大学董事会 用非蛋白质水解激活的凝血酶受体的激动剂刺激软骨生长
CN100509055C (zh) 2001-07-27 2009-07-08 奥索洛吉艾斯有限公司 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡
TW200407905A (en) * 2002-11-06 2004-05-16 Leadtek Research Inc Data write-in and read-out method of flash memory and circuit thereof
DE602004005564T2 (de) 2003-12-31 2007-12-13 Orthologic Corp., Tempe Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten

Also Published As

Publication number Publication date
US20050153893A1 (en) 2005-07-14
CA2491135A1 (en) 2004-01-15
DE60313982T2 (de) 2008-01-17
AU2003247848B2 (en) 2006-12-21
EP1539800B1 (en) 2007-05-23
EP1539800A4 (en) 2005-11-16
EP1539800A2 (en) 2005-06-15
US7456250B2 (en) 2008-11-25
ATE362939T1 (de) 2007-06-15
AU2003247848A1 (en) 2004-01-23
US7919457B2 (en) 2011-04-05
JP2006507229A (ja) 2006-03-02
WO2004005317A3 (en) 2004-09-30
US20090124550A1 (en) 2009-05-14
WO2004005317A2 (en) 2004-01-15
DE60313982D1 (de) 2007-07-05
AU2003247848C1 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
US7919457B2 (en) Thrombin peptide derivative dimers
US7875588B2 (en) Methods of therapy using pharmaceutical composition for thrombin peptide derivatives
CN1455678A (zh) 用凝血酶派生的肽的治疗方法
JP2004503596A (ja) トロンビンペプチド誘導体による骨成長の刺激
JP2006514822A (ja) トロンビンペプチド誘導体
US20090060999A1 (en) Protein formulation
JP2001122800A (ja) 骨シアロプロティンを含む結合組織修復促進組成物及び骨シアロプロティンの使用方法
JP2005519067A (ja) トロンビンペプチド誘導体を用いた骨成長および軟骨形成の刺激
EP1830863A2 (en) Protein formulation
HK1080390B (en) Pharmaceutical composition for thrombin peptide derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090330

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101025

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101222

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140121

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140121

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees